This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Lemelson Capital Says Ligand Pharmaceuticals' $225M Debt Issuance Solidifies Company's Insolvency, Substantially Raises Specter Of Bankruptcy

Stocks in this article: AMGN LGND

MARLBOROUGH, Mass., Aug. 14, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today released a research note and audio interview by the firm's Chief Investment Officer Emmanuel Lemelson, raising new and escalated concerns about the going concern risk and bankruptcy prospects of the troubled drug delivery company Ligand Pharmaceuticals (NASDAQ: LGND).  The new concerns, raised in Lemelson's August 13, 2014 interview with the financial media outlet Benzinga, follow Ligand's August 11, 2014 announcement that it would issue $225 million of convertible senior debt, a portion of which would be used to repurchase shares in private transactions from shareholders.

Audio of the August 13, 2014 interview can be heard here:

Lemelson Capital's August 14, 2014 research note on Ligand can be read here:

In today's research note, Lemelson Capital amended previous research reports on Ligand with even deeper concerns about the company's projected forward revenues based on yesterday's announcement by Amgen (NASDAQ: AMGN) that the Phase 3 clinical trial for Kyprolis® has failed to demonstrate improved overall survival in use with relapsed multiple mylenoma patients.  The failure of Kyprolis® in this clinical trial will almost certainly severely impair Ligand's already declining revenues.

"Ligand's announcements this week are ominous for many reasons," Lemelson said today.  "First, Ligand's debt issuance appears necessitated by the fact that large institutional shareholders are expressing their intention to get out of the stock, which is understandable given the company's rapidly deteriorating financial condition," he said.  "Second, the company has nominal tangible equity of just $21,000 against an astounding market capitalization of about $1.1 billion and is now assuming vast and costly debt at a 15 percent upfront premium, which they appear to wrongly represent as being offered at  a very low 0.75% coupon," he added. "And finally," Lemelson said, "Ligand has traded at an extraordinarily overvalued multiple based largely on speculation that Kyprolis® would show promise as a second-line therapy in multiple mylenoma treatment, which now appears highly unlikely to materialize."  

In the interview with Benzinga and today's accompanying research note, Lemelson addresses Ligand's insolvency, the details of its remarkably costly debt offering, and the mounting prospect for the company's bankruptcy.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs